US FDA grants Lynparza Orphan Drug Designation for pancreatic cancer
Fourth Orphan Drug Designation in the US for AstraZeneca and MSD’s LynparzaAstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) today announced that they were granted orphan drug designation (ODD) by the US Food and Drug Administration (FDA) for Lynparza (olaparib) for the treatment of pancreatic cancer. Pancreatic cancer is a rare, life-threatening disease that accounts for about 3% of all cancers in the US.[i]